Treatment of Arterial Hypertension in Obese Patients

Seminars in Nephrology

Volumn 33, Issue 1, 2013, Pages 66-74

  Wenzel, Ulrich O ^a   Benndorf, Ralf ^b   Lange, Sascha ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Antihypertensive treatment; Arterial hypertension; Obesity

Indexed keywords

ALDOSTERONE; ALISKIREN; AMLODIPINE; ANGIOTENSIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; HYDROCHLOROTHIAZIDE; INSULIN; IRBESARTAN; LISINOPRIL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; RAMIPRIL; RENIN; RENIN INHIBITOR; ROSIGLITAZONE; SODIUM; SPIRONOLACTONE; TELMISARTAN; THIAZIDE DIURETIC AGENT; TRIACYLGLYCEROL; UNINDEXED DRUG; VALSARTAN;

ADD ON THERAPY; ADIPOSE TISSUE; ALCOHOL WITHDRAWAL; ARTICLE; BLOOD PRESSURE REGULATION; CHILD CARE; CLINICAL TRIAL (TOPIC); COUGHING; DIABETIC NEPHROPATHY; DIASTOLIC BLOOD PRESSURE; DRUG COST; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG USE; DYSLIPIDEMIA; GYNECOMASTIA; HUMAN; HYPERKALEMIA; HYPERTENSION; INSULIN SENSITIVITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATHOGENESIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SIDE EFFECT; SODIUM RESTRICTION; SODIUM RETENTION; SYSTOLIC BLOOD PRESSURE; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN; WEIGHT REDUCTION;

ANTIHYPERTENSIVE AGENTS; HUMANS; HYPERTENSION; INSULIN RESISTANCE; KIDNEY; LIPIDS; OBESITY; RENIN-ANGIOTENSIN SYSTEM;

EID: 84873183866     PISSN: 02709295     EISSN: 15584488     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2012.12.009     Document Type: Article

References (61)

1. Kotchen T.A. Obesity-related hypertension: epidemiology, pathophysiology, and clinical management. Am J Hypertens 2010, 23:1170-1178.
2. Jordan J., Yumuk V., Schlaich M., et al. Joint statement of the European Association for the Study of Obesity and the European Society of Hypertension: obesity and difficult to treat arterial hypertension. J Hypertens 2012, 30:1047-1055.
3. Doll S., Paccaud F., Bovet P., Burnier M., Wietlisbach V. Body mass index, abdominal adiposity and blood pressure: consistency of their association across developing and developed countries. Int J Obes Relat Metab Disord 2002, 26:48-57.
4. Bramlage P., Pittrow D., Wittchen H.U., et al. Hypertension in overweight and obese primary care patients is highly prevalent and poorly controlled. Am J Hypertens 2004, 17:904-910.
5. Calhoun D.A., Jones D., Textor S., et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation 2008, 117:e510-e526.
6. Frohlich E.D. Clinical management of the obese hypertensive patient. Cardiol Rev 2002, 10:127-138.
7. Dentali F., Sharma A.M., Douketis J.D. Management of hypertension in overweight and obese patients: a practical guide for clinicians. Curr Hypertens Rep 2005, 7:330-336.
8. Wenzel U.O., Krebs C. Treatment of arterial hypertension in obese patients. Contrib Nephrol 2006, 151:230-242.
9. Wenzel U.O., Krebs C. Management of arterial hypertension in obese patients. Curr Hypertens Rep 2007, 9:491-497.
10. Chobanian A.V., Bakris G.L., Black H.R., et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003, 289:2560-2572.
11. Engeli S., Sharma A.M. Emerging concepts in the pathophysiology and treatment of obesity-associated hypertension. Curr Opin Cardiol 2002, 17:355-359.
12. Sharma A.M., Rossner S. Who cares about the obese hypertensive patient?. J Intern Med 2002, 251:369-371.
13. Jones D.W., Miller M.E., Wofford M.R., et al. The effect of weight loss intervention on antihypertensive medication requirements in the hypertension Optimal Treatment (HOT) study. Am J Hypertens 1999, 12:1175-1180.
14. Jansen P.M., Danser J.A., Spiering W., van den Meiracker A.H. Drug mechanisms to help in managing resistant hypertension in obesity. Curr Hypertens Rep 2010, 12:220-225.
15. Reisin E., Weir M.R., Falkner B., et al. Lisinopril versus hydrochlorothiazide in obese hypertensive patients: a multicenter placebo-controlled trial. Treatment in Obese Patients With Hypertension (TROPHY) Study Group. Hypertension 1997, 30:140-145.
16. Grassi G., Seravalle G., Dell'Oro R., et al. Comparative effects of candesartan and hydrochlorothiazide on blood pressure, insulin sensitivity, and sympathetic drive in obese hypertensive individuals: results of the CROSS study. J Hypertens 2003, 21:1761-1769.
17. Jordan J., Engeli S., Boschmann M., et al. Hemodynamic and metabolic responses to valsartan and atenolol in obese hypertensive patients. J Hypertens 2005, 23:2313-2318.
18. Jordan J., Engeli S., Boye S.W., Le Breton S., Keefe D.L. Direct renin inhibition with aliskiren in obese patients with arterial hypertension. Hypertension 2007, 49:1047-1055.
19. Townsend R.R., Peixoto A.J. Hypertension. NephSAP by The American Society of Nephrology 2012, 11:69-134.
20. Dorresteijn J.A., Visseren F.L., Spiering W. Mechanisms linking obesity to hypertension. Obes Rev 2012, 13:17-26.
21. Hall J.E., da Silva A.A., do Carmo J.M., et al. Obesity-induced hypertension: role of sympathetic nervous system, leptin, and melanocortins. J Biol Chem 2010, 285:17271-17276.
22. Willenberg H.S., Schinner S., Ansurudeen I. New mechanisms to control aldosterone synthesis. Horm Metab Res 2008, 40:435-441.
23. Rocchini A.P. Cardiovascular regulation in obesity-induced hypertension. Hypertension 1992, 19(Suppl):I56-I60.
24. Sharma A.M. Is there a rationale for angiotensin blockade in the management of obesity hypertension?. Hypertension 2004, 44:12-19.
25. Wofford M.R., Hall J.E. Pathophysiology and treatment of obesity hypertension. Curr Pharm Des 2004, 10:3621-3637.
26. Cali A.M., Caprio S. Obesity in children and adolescents. J Clin Endocrinol Metab 2008, 93(Suppl 1):S31-S36.
27. Neter J.E., Stam B.E., Kok F.J., Grobbee D.E., Geleijnse J.M. Influence of weight reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertension 2003, 42:878-884.
28. Basso N., Terragno N.A. History about the discovery of the renin-angiotensin system. Hypertension 2001, 38:1246-1249.
29. Wenzel U.O. Angiotensin-converting enzyme inhibitors and progression of renal disease: evidence from clinical studies. Contrib Nephrol 2001, 135:200-211.
30. Wolf G., Butzmann U., Wenzel U.O. The renin-angiotensin system and progression of renal disease: from hemodynamics to cell biology. Nephron Physiol 2003, 93:P3-P13.
31. Yusuf S., Sleight P., Pogue J., et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000, 342:145-153.
32. Scheen A.J. Prevention of type 2 diabetes mellitus through inhibition of the renin-angiotensin system. Drugs 2004, 64:2537-2565.
33. McFarlane S.I., Provilus A., Shin J.J. Diabetes prevention between RAAS inhibition and PPAR-gamma stimulation: the diabetes reduction assessment with ramipril and rosiglitazone medication (DREAM) trial. J Cardiometab Syndr 2007, 2:149-150.
34. Sharma A.M., Pischon T., Engeli S., Scholze J. Choice of drug treatment for obesity-related hypertension: where is the evidence?. J Hypertens 2001, 19:667-674.
35. Zanella M.T., Kohlmann O., Ribeiro A.B. Treatment of obesity hypertension and diabetes syndrome. Hypertension 2001, 38:705-708.
36. Sharma A.M., Pischon T., Hardt S., Kunz I., Luft F.C. Hypothesis: beta-adrenergic receptor blockers and weight gain: a systematic analysis. Hypertension 2001, 37:250-254.
37. Brenner B.M., Cooper M.E., de Zeeuw D., et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001, 345:861-869.
38. Dahlof B., Devereux R.B., Kjeldsen S.E., et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002, 359:995-1003.
39. Wolf G., Ritz E. Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications. Kidney Int 2005, 67:799-812.
40. Yusuf S., Teo K.K., Pogue J., et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008, 358:1547-1559.
41. McMurray J.J., Abraham W.T., Dickstein K., et al. Aliskiren, ALTITUDE, and the implications for ATMOSPHERE. Eur J Heart Fail 2012, 14:341-343.
42. Muller D.N., Luft F.C. Direct renin inhibition with aliskiren in hypertension and target organ damage. Clin J Am Soc Nephrol 2006, 1:221-228.
43. Boschmann M., Nussberger J., Engeli S., et al. Aliskiren penetrates adipose and skeletal muscle tissue and reduces renin-angiotensin system activity in obese hypertensive patients. J Hypertens 2012, 30:561-566.
44. Steckelings U.M., Paulis L., Namsolleck P., Unger T. AT2 receptor agonists: hypertension and beyond. Curr Opin Nephrol Hypertens 2012, 21:142-146.
45. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002, 288:2981-2997. ALLHAT Collaborative Research Group.
46. Kostis J.B., Wilson A.C., Freudenberger R.S., et al. Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes. Am J Cardiol 2005, 95:29-35.
47. Aksnes T.A., Kjeldsen S.E., Rostrup M., et al. Impact of new-onset diabetes mellitus on cardiac outcomes in the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial population. Hypertension 2007, 50:467-473.
48. Calhoun D.A. Use of aldosterone antagonists in resistant hypertension. Prog Cardiovasc Dis 2006, 48:387-396.
49. Saha C., Eckert G.J., Ambrosius W.T., et al. Improvement in blood pressure with inhibition of the epithelial sodium channel in blacks with hypertension. Hypertension 2005, 46:481-487.
50. Wenzel U., Stange D., Dusing R. A simple test to appreciate compliance with antihypertensive drug therapy. J Hypertens 2012, 30:624.
51. de Souza F., Muxfeldt E., Fiszman R., Salles G. Efficacy of spironolactone therapy in patients with true resistant hypertension. Hypertension 2010, 55:147-152.
52. Scholze J., Grimm E., Herrmann D., Unger T., Kintscher U. Optimal treatment of obesity-related hypertension: the Hypertension-Obesity-Sibutramine (HOS) study. Circulation 2007, 115:1991-1998.
53. Lindholm L.H., Carlberg B., Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension?. A meta-analysis. Lancet 2005, 366:1545-1553.
54. Schmieder R.E., Gatzka C., Schachinger H., Schobel H., Ruddel H. Obesity as a determinant for response to antihypertensive treatment. BMJ 1993, 307:537-540.
55. White W.B., Elliott W.J., Johnson M.F., Black H.R. Chronotherapeutic delivery of verapamil in obese versus non-obese patients with essential hypertension. J Hum Hypertens 2001, 15:135-141.
56. Dahlof B., Sever P.S., Poulter N.R., et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005, 366:895-906.
57. Pollare T., Lithell H., Selinus I., Berne C. Application of prazosin is associated with an increase of insulin sensitivity in obese patients with hypertension. Diabetologia 1988, 31:415-420.
58. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2000, 283:1967-1975. ALLHAT Collaborative Research Group.
59. Mahfoud F., Schlaich M., Kindermann I., et al. Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: a pilot study. Circulation 2011, 123:1940-1946.
60. Witkowski A., Prejbisz A., Florczak E., et al. Effects of renal sympathetic denervation on blood pressure, sleep apnea course, and glycemic control in patients with resistant hypertension and sleep apnea. Hypertension 2011, 58:559-565.
61. Steichen O., Sapoval M., Frank M., et al. [Renal-nerve ablation in patients with resistant hypertension: caution is still needed]. Presse Med 2012, 41:349-357.